ArticleBone marrow transplantation2012

Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.

S M Sengsayadeth et al.PubMed ↗Publisher ↗

No numbers read from the abstract.